4//SEC Filing
PERRY MARK W 4
Accession 0001181431-12-043174
CIK 0001386858other
Filed
Aug 1, 8:00 PM ET
Accepted
Aug 2, 2:12 PM ET
Size
51.5 KB
Accession
0001181431-12-043174
Insider Transaction Report
Form 4
PERRY MARK W
10% Owner
Transactions
- Conversion
Common Stock
2012-07-31+611,185→ 615,119 total(indirect: See Note 1) - Other
Common Stock
2012-07-31−51,119→ 1,588,099 total(indirect: See Note 1) - Conversion
Common Stock
2012-07-31+2,043→ 1,592,185 total(indirect: See Note 1) - Exercise of In-Money
Common Stock
2012-07-31+125,291→ 1,639,218 total(indirect: See Note 1) - Conversion
Common Stock
2012-07-31+434,096→ 2,026,281 total(indirect: See Note 1) - Exercise of In-Money
Common Stock Warrant (right to buy)
2012-07-31−125,291→ 0 total(indirect: See Note 1)Exercise: $4.08→ Common Stock (125,291 underlying) - Conversion
Series C-2 Preferred Stock
2012-07-31−2,043→ 0 total(indirect: See Note 1)→ Common Stock (2,043 underlying) - Exercise of In-Money
Series C-2 Preferred Stock
2012-07-31+53,787→ 53,787 total(indirect: See Note 1)→ Common Stock (53,787 underlying) - Conversion
Convertible Promissory Note
2012-07-31→ 0 total(indirect: See Note 1)Exercise: $10.00→ Common Stock (177,481 underlying) - Conversion
Common Stock
2012-07-31+180,459→ 2,206,740 total(indirect: See Note 1) - Conversion
Convertible Promissory Note
2012-07-31→ 0 total(indirect: See Note 1)Exercise: $10.00→ Common Stock (434,096 underlying) - Conversion
Common Stock
2012-07-31+898,808→ 1,513,927 total(indirect: See Note 1) - Conversion
Common Stock
2012-07-31+177,481→ 2,384,221 total(indirect: See Note 1) - Conversion
Series C-1 Preferred Stock
2012-07-31−611,185→ 0 total(indirect: See Note 1)→ Common Stock (611,185 underlying) - Exercise of In-Money
Series C-2 Preferred Stock
2012-07-31+53,787→ 53,787 total(indirect: See Note 1)→ Common Stock (53,787 underlying) - Other
Series C-2 Preferred Stock
2012-07-31$10.00/sh−51,744$517,440→ 2,043 total(indirect: See Note 1)→ Common Stock (51,744 underlying) - Exercise of In-Money
Preferred Stock Warrant (right to buy)
2012-07-31−53,787→ 0 total(indirect: See Note 1)Exercise: $9.62→ Series C-2 Preferred Stock (53,787 underlying) - Conversion
Series C-2 Preferred Stock
2012-07-31−2,043→ 0 total(indirect: See Note 1)→ Common Stock (2,043 underlying) - Conversion
Convertible Promissory Note
2012-07-31→ 0 total(indirect: See Note 1)Exercise: $10.00→ Common Stock (180,459 underlying) - Conversion
Common Stock
2012-07-31+2,043→ 1,590,142 total(indirect: See Note 1) - Purchase
Common Stock
2012-07-31$10.00/sh+500,000$5,000,000→ 2,884,221 total(indirect: See Note 1) - Conversion
Series C-2 Preferred Stock
2012-07-31−898,808→ 0 total(indirect: See Note 1)→ Common Stock (898,808 underlying) - Exercise of In-Money
Preferred Stock Warrant (right to buy)
2012-07-31−53,787→ 0 total(indirect: See Note 1)Exercise: $9.62→ Series C-2 Preferred Stock (53,787 underlying) - Other
Series C-2 Preferred Stock
2012-07-31$10.00/sh−51,744$517,440→ 2,043 total(indirect: See Note 1)→ Common Stock (51,744 underlying)
Footnotes (9)
- [F1]The Reporting Person is a manager of NEA 12 GP, LLC, the sole general partner of NEA Partners 12, Limited Partnership, the sole general partner of New Enterprise Associates 12, Limited Partnership ("NEA 12"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities of the Issuer held by NEA 12 in which the Reporting Person has no pecuniary interest.
- [F2]Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of convertible preferred stock automatically converted into one share of common stock. The convertible preferred stock had no expiration date.
- [F3]Immediately prior to the closing, the warrants automatically net exercised by their terms, which allowed the holder to pay the exercise price of the warrants by forfeiting a portion of the exercised warrant shares with a value equal to the aggregate exercise price.
- [F4]These shares reflect the net exercise of the common stock warrant pursuant to its terms into 74,172 shares of the Issuer's common stock.
- [F5]Notes and accrued interest in the aggregate of $4,340,965 converted automatically immediately prior to the closing of the Issuer's initial public offering into shares of common stock at a conversion price of $10.00 per share, which is the initial public offering price per share.
- [F6]Notes and accrued interest in the aggregate of $1,804,594 converted automatically immediately prior to the closing of the Issuer's initial public offering into shares of common stock at a conversion price of $10.00 per share, which is the initial public offering price per share.
- [F7]Notes and accrued interest in the aggregate of $1,774,817 converted automatically immediately prior to the closing of the Issuer's initial public offering into shares of common stock at a conversion price of $10.00 per share, which is the initial public offering price per share.
- [F8]Immediately prior to the closing, the warrants automatically net exercised by their terms into Series C-2 preferred stock, which allowed the holder to pay the exercise price of the warrants by forfeiting a portion of the exercised warrant shares with a value equal to the aggregate exercise price. The convertible preferred stock had no expiration date.
- [F9]These shares reflect the net exercise of the preferred stock warrant pursuant to its terms into 2,043 shares of the Issuer's Series C-2 preferred stock.
Documents
Issuer
HYPERION THERAPEUTICS INC
CIK 0001386858
Entity typeother
Related Parties
1- filerCIK 0001062466
Filing Metadata
- Form type
- 4
- Filed
- Aug 1, 8:00 PM ET
- Accepted
- Aug 2, 2:12 PM ET
- Size
- 51.5 KB